Cell Therapeutics
–Pixantrone
—–PIX 301
Genta
–Genasense
—–GM 301
—–AGENDA
—–CLL FDA Meeting (G3139 Trial)
—–2009 ASCO Data
HemispherX
–Ampligen
—–Results from AMP-516, press release
—–Additional data released from the Amp-516 study
—–Amp 516 Summary from the May 2009 IACFSME (Please scroll down to session 1, 4th parag.)
—–HemispherX’s Ampligen The Story (I found this under scholarly Journals for Ampligen, I highly recommend reading it)
YM BioSciences
–Nimotuzumab
—–Phase III data for Head and Neck cancer comparison between Erbitux YM Press Release
—–Nimotuzumab Corporate Presentation here
—–Nimotuzumab AACR 2009 Meeting Poster here
—–ERbitux NEJM article that Nimotuzumab is used for a comparison here.
Twitter
“2009 ASCO Preliminary data for Agenda”
The information pointed to has nothing to do with AGENDA. No preliminary data is available for the AGENDA trial yet.
“2009 ASCO Extrapolated Preliminary data for Agenda”
The information pointed to has nothing to do with extrapolated preliminary data from AGENDA either. No preliminary data is available from the AGENDA trial yet.
Hand picked, subset data from the first failed trial has been presented in the form of ‘anticipated results’ though.
Moose I agree with you partially, but the reason this data was presented at ASCO was due to the fact that Temodar® in combination with Genasesne was used in a pilot study to evaluate Melanoma in Normal LDH patients. The reason I stated that this is an extrapolated version of AGENDA data is due to the fact that Temodar® is the active metabolite of dacarbazine, which as you know was the combination in the first trial for melanoma. Additionally, the patients in this trial also had the same LDH biomarker. I guess it all depends on what you think Genta’s intention was for the release of data for a similar patient group and a similar molecular compound. I will change the name for you, but I think we both know that Genta’s intention was for investors to try and extrapolate data and apply it to the AGENDA trial. If you notice at the bottom of the release the first reference is given to the AGENDA trial.
Thanks for all the detailed information.
It has helped me to decide if I want to stay long with this stock.
Any chance for an article on ADLS?
They recent had some bad news regarding approval of a novel antibiotic for hospital acquired pneumonia, but now they’re pushing the drug for an anthrax indication. A lot of people got stung with their recent PPS drop, and some are holding on long for a rise in the near future. Your analysis on HEB and CTIC has been spot on, so I’m sure many would appreciate your opinion on ADLS too.
Another request for information… AMAR. I’ve been trading this on an off for a few weeks, riding it between $0.15 and $0.25, but there never seems to be any news associated with the rises and falls. It’s a fairly quiet stock, so unlikely just pump-and-dumping by the crowds on the Google and Yahoo finance message-boards. Any background on AMAR?
i was wondering about a company ARNA…..any knowledge is helpful
Any chance you can do an article on Antigen AE37 and the recent results
of 0/49 relapses after 13 Months of Breast Cancer Treatment.
Some are calling it a cure for Cancer.
http://finance.yahoo.com/news/Generex-Clarifies-Previous-pz-3473880250.html?x=0&.v=1
Thanks,
what up to date info if any is available on the trials for generex products {gnbt} ?
I will do an in depth analysis on Generex’s Oral-Lyn when I have a little more info on the Phase III trial. I am expecting some heavy info about two weeks before the ADA’s 70th Scientific Sessions 2010 conference June 25- 29, 2010. The link to the site is here http://professional.diabetes.org/Congress_Display.aspx?TYP=9&SID=163&CID=64574, abstracts should be released two weeks beforehand.
I read all your posts with great interest. Thank you for all the hard work you put into these and for the clear way your articles are written. If you ever have the time, could you look at IMUC (ImmunCellular Therapeutics)? They released data at ASCO ‘09 last May that seemed to indicate how well their compound ICT-107 was doing. The company sated overall progression free survival was extended by over 12 months for brain tumor patients and they have more in the pipeline. I can’t understand how this company does not get more press. Any thoughts you have would be greatly appreciated and again, thanks for all your intelligent, well-written posts.
AETERNA ZENTARIS INC.
Phase 3
——————————————————————-Perifosine
(Multiple myeloma)
SolorelTM (AEZS-130)
Diagnostic in adult growth hormone deficiency (Endocrinology)
http://www.zentaris.com/en/page.php?p=12
Would you please post the new link to the story of ampligen from HEB?
current link does not work
I’m sorry which story are you referring to and I can email it to you directly.